Growth in Gene and Cell Therapy Trials According to the American Society of Gene & Cell Therapy (ASGCT)-Citeline Q1 2025 report, the combined gene, cell and RNA therapy pipeline featured 4,418 active programs, including 2,155 gene therapies and 966 non-genetically modified cell therapies with 79 new gene therapy trials (57% in oncology) and 27 new cell therapy trials (74% in non-oncology) initiated that quarter
Tissue repair across multiple organ systems The review documents GHK-Cu's regenerative effects across skin, lung connective tissue, bone, liver, and stomach lining
It reported rapid metabolism and a prototype half-life under 30 minutes, but it did not test an oral tablet, delayed-release capsule, or buccal spray
Administering by Injection allows you to bypass any absorption issues that your gut might have, leading to a full dose to be utilized by the body
BPC-157 advances repair through several complementary mechanisms: stimulating new microvasculature for oxygen and nutrient delivery, strengthening collagen networks, and preserving tissue integrity